Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.41 |
| ▸ | TK1 | P04183 | 3/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23996235 | 0.88 | CYP3A4 (0.57) | CYP3A4CYP2C9BTN3A1TYMS | |
| SCHEMBL16575709 | 0.88 | CYP3A4 (0.57) | CYP3A4CYP2C9BTN3A1TYMS | |
| Fosclevudine Alafenamide SCHEMBL17859276 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS | |
| Fosclevudine Alafenamide SCHEMBL21577294 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS | |
| Fosclevudine Alafenamide SCHEMBL19825437 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS | |
| Fosclevudine Alafenamide SCHEMBL24723318 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS | |
| SCHEMBL23720991 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TK1TYMS | |
| Fosclevudine Alafenamide SCHEMBL24737195 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS | |
| Fosclevudine Alafenamide SCHEMBL21577296 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS | |
| Fosclevudine Alafenamide SCHEMBL17859295 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261046-A1 | COMPOSITIONS AND METHODS OF TREATING HEPATITIS D AND HEPATITIS B/HEPATITIS D CO-INFECTIONS WITH PHOSPHORAMIDATE CLEVUDINE PRODRUGS | Antios Therapeutics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |